Evia Bio, Inc. — SEC Form D Filing

Evia Bio, Inc. filed an SEC Form D on September 28, 2026, reporting $5.45M raised in Biotechnology.

Form D filing details

Filing
SEC Form D
Filing date
September 28, 2026
Amount reported
$5.45M
Round stage
Series A, as a $5.4 million raise is the typical size for an early-stage biotechnology company transitioning from laboratory formulation to commercial scaling and clinical validation.
Industry
Biotechnology
Website
https://eviabio.com

What the company does

Securities: Equity. Exemption: Rule 506(b). Incorporated: DELAWARE

Problem

Conventional cryopreservation methods for cell and gene therapies rely on toxic agents like dimethyl sulfoxide that damage cells, reduce therapeutic efficacy, and cause adverse patient reactions.

Solution

Evia Bio develops safe, non-toxic, and DMSO-free cryopreservation formulations and technologies to preserve cell and gene therapies without compromising cell viability or patient safety.

Why now

The rapid commercialization and clinical scaling of cell and gene therapies demand safer, highly reliable, and regulatory-compliant preservation methods that eliminate toxic additives.

Source: SEC EDGAR Form D filing